Abstracts tagged "IL-1"

Abstract Number: 028 • 2020 Pediatric Rheumatology Symposium
A Randomized, Double-blind, Placebo-controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease
Laura Schanberg¹, Peter Nigrovic ², Ashley Cooper ³, Winn Chatham ⁴, Shoghik Akoghlanian ⁵, Namrata Singh ⁶, C. Egla Rabinovich ⁷, Akaluck Thatayatikom ⁸, Alysha Taxter ⁹, Jonathan Hausmann ¹⁰, Milan Zdravkovic ¹¹, Sven Ohlman ¹¹, Henrik Andersson ¹¹, Susanna Cederholm ¹², Gunilla Huledal ¹¹, Rayfel Schneider ¹³ and Fabrizio De Benedetti ¹⁴, ¹Duke Children's Hospital & Health Center, Durham, North Carolina, ²Boston Children's Hospital, Boston, Massachusetts, ³Children's Mercy Kansas City, Kansas City, ⁴University of Alabama at Birmingham, Birmingham, ⁵Nationwide Children's Hospital, Columbus, ⁶University of Iowa Hospitals and Clinics, Iowa, Iowa, ⁷Duke University Hospital, Durham, ⁸University of Florida, Gainesville, ⁹Wake Forest Baptist Medical Center, Winston-Salem, ¹⁰Division of Immunology, Boston Children's Hospital; Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ¹¹Sobi, Stockholm, Sweden, ¹²Stockholm, Sweden, ¹³The Hospital for Sick Children, Toronto, Canada, ¹⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) are rare systemic disorders of auto-inflammatory nature. There is a growing understanding that SJIA…
Abstract Number: 1238 • 2019 ACR/ARP Annual Meeting
Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter
Félix Renaudin ¹, Laure Campillo-Gimenez ², Florence Castelli ³, François Fenaille ³, Aurélie Prignon ⁴, Christele Combes ⁵, Martine Cohen-Solal ¹, Frédéric Lioté ⁶ and Hang Korng Ea¹, ¹Université Paris, INSERM UMR1132 BIOSCAR, Paris, France, ²Université Paris, INSERM UMR1132 BIOSCAR, San Diego, ³CEA Paris-Saclay, Laboratoire d’Etudes du Métabolisme des Médicaments, Saclay, France, ⁴UMS28 Phénotypage du petit animal, Laboratoire d'Imagerie Moléculaire Positonique (LIMP), Sorbonne Univerity, Paris, France, ⁵CIRIMAT, Université de Toulouse, INPT,UPS,CNRS,ENSIACET, Toulouse, France, ⁶Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France
Background/Purpose: Monosodium urate (MSU) andmonoclinic calcium pyrophosphate dihydrated(mCPPD)crystals are responsible for relapsing acute arthritis which is driven by interleukin 1β (IL-1β).IL-1βproductionrelies onNLRP3 inflammasome activationleading to…
Abstract Number: 2905 • 2019 ACR/ARP Annual Meeting
Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial
Allan Klein ¹, David Lin ², Paul Cremer ¹, Saifullah Nasir ³, Sharon Crugnale ⁴, Larisa Collins ⁴, Fang Fang ⁴, Anna Beutler ⁴ and John F Paolini⁴, ¹Cleveland Clinic, Cleveland, OH, ²Minneapolis Heart Institute - Minneapolis, Minneapolis, MN, ³Stat! Cardiologist, Chicago, IL, ⁴Kiniksa Pharmaceuticals Corp, lexington, MA
Background/Purpose: Recurrent pericarditis (RP) is characterized by the recurrence of pericarditis signs and symptoms after a symptom-free period of ≥4 to 6 weeks and affects…
Abstract Number: 2855 • 2018 ACR/ARHP Annual Meeting
Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Dira
Jasmin B. Kuemmerle-Deschner¹, Konstanze Hoertnagel², Susanne Schlipf³, Sandra Hansmann⁴, Toni Hospach⁵, Ilias Tsiflikas⁶, Xiao Liu⁷, Susanne Benseler⁸ and Alexander Weber⁷, ¹Department of Pediatrics, Division of Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ²Praxis für Humangenetik Tübingen,Tuebingen, Germany, Tuebingen, Germany, ³Kinderarztpraxis Dr. Lakner, Schwäbisch Gmünd, Germany, Schwäbisch Gmünd, Germany, ⁴Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, Tuebingen, Germany, ⁵Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, ⁶Division of Pediatric Radiology, Department of Radiology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ⁷Department of Immunology, University of Tübingen, Tübingen, Germany, Tuebingen, Germany, ⁸Rheumatology, Department of Paediatrics, Alberta Children's Hospital, University of Calgary, Alberta, Canada, Calgary, AB, Canada
Background/Purpose: Deficiency of the Interleukin-1 receptor antagonist (DIRA) is an autoinflammatory disease of infancy characterized by severe systemic inflammation with bone and skin involvement. This…
Abstract Number: 2965 • 2018 ACR/ARHP Annual Meeting
Targeting Glucose Metabolism in the Murine Air Pouch Model of Acute Gouty Inflammation
Anyan Cheng¹, Roxana Coras^1,2, Robert Terkeltaub^3,4, Ru Liu-Bryan^1,3 and Monica Guma^1,2, ¹Medicine, University of California San Diego, La Jolla, CA, ²Medicine, Autonomous University of Barcelona, Bellatera, Spain, ³VA San Diego Healthcare System, San Diego, CA, ⁴Medicine, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA
Background/Purpose: Emerging evidence indicates that macrophage activation is critically supported by glucose metabolic shifts. Although macrophages are key contributors to inflammation, little is known about…
Abstract Number: 2968 • 2018 ACR/ARHP Annual Meeting
Role of Choline in Gouty Inflammation
Elsa Sanchez-Lopez¹, Zhenyu Zhong¹, Alex Stubelius², Shannon R Sweeney³, Ru Liu-Bryan^4,5, Juan Carlos Lacal⁶, Stefano Tiziani^3,7,8, Robert Terkeltaub^4,9, Monica Guma⁹ and Michael Karin¹, ¹Department of Pharmacology, School of Medicine. UCSD., La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA, ³Department of Nutritional Sciences. The University of Texas at Austin., Austin, TX, ⁴VA San Diego Healthcare System, San Diego, CA, ⁵Medicine-Rheumatology, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA, ⁶Translational Oncology. Department of Oncology, Hospital Universitario Fuenlabrada, Madrid, Spain, ⁷Department of Molecular Biosciences, College of Natural Sciences. The University of Texas at Austin., Austin, TX, ⁸Department of Pediatrics, Dell Medical School. The University of Texas at Austin., Austin, TX, ⁹Medicine, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA
Background/Purpose: Gout is characterized by deposition of monosodium urate (MSU) crystals in articular joints, where they activate macrophages inducing NLRP3 inflammasome activation and bioactive IL-1β…
Abstract Number: 1985 • 2018 ACR/ARHP Annual Meeting
IL-1β Inhibits the Expression of Dickkopf-1, an Antagonist of the Wnt-β-Catenin Signaling Pathway: A Possible Role of Inflammasome in Dysregulation of Endochondral Ossification
Satoshi Yamasaki¹, Yusuke Yoshida², Katsuhiro Oi², Tatsuomi Kuranobu², Takaki Nojima², Hiroaki Ida³ and Eiji Sugiyama⁴, ¹Division of Rheumatology, Kurume University Medical Center, Fukuoka, Japan, ²Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ³Respiorogy, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, ⁴Department of Clinical Immunology and Rheumatology, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Aberrant endochondral bone formation in the physis is a unique bone lesion in neonatal-onset multisystem inflammatory disease (NOMID), also called chronic infantile neurologic cutaneous…
Abstract Number: 76 • 2017 ACR/ARHP Annual Meeting
TNF-α Potentiates Uric Acid-Induced Interleukin-1β Secretion in Human Neutrophils
Shuzo Sato¹, Makiko Yashiro¹, Tomoyuki Asano¹, Tomohiro Koga², Eiji Suzuki¹, Hiroko Kobayashi¹, Hiroshi Watanabe¹ and Kiyoshi Migita³, ¹Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Fukushima Medical University School of Medicine, Fukushima, Japan
Background/Purpose: Gout is an inflammatory arthropathy due to the deposition of uric acid (monosodium urate: MSU) crystals in synovial tissue. MSU leads to activate nucleotide-binding…
Abstract Number: 77 • 2017 ACR/ARHP Annual Meeting
Platelets Induce IL-1b Production in Human Monocytes through NLRP3 Inflammasome Activation
Shota Nakano¹, Hiroki Mitoma¹, Shotaro Kawano¹, Shoichiro Inokuchi², Masahiro Ayano¹, Yasutaka Kimoto³, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi⁴ and Hiroaki Niro⁵, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Recent studies have revealed that platelets play pivotal roles in inflammation in addition to hemostasis. The thrombus induces subsequent local inflammation and reversely the…
Abstract Number: 1163 • 2017 ACR/ARHP Annual Meeting
A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects
Ahmet Gul¹, Sibel Ulker², Recep Selim Senturk², Ugur Onsel Turk², Cemil Gurgun², Yan Lavrovsky³, Mikhail Samsonov⁴, Sebnem Ozen⁵ and Serdar Altinel⁶, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Ege University Drug Development and Pharmacokinetics Research and Application Centre (ARGEFAR), Izmir, Turkey, ³R-Pharm Overseas, Inc.,, San Diego, CA, ⁴Medical Department, R-Pharm JSC, Moscow, Russian Federation, ⁵Clinical Trial Department, TRPHARM İlac A.S., Istanbul, Turkey, ⁶linical Trial Department, TRPHARM İlac A.S., Istanbul, Turkey
Background/Purpose: Interleukin-1 (IL-1) is highly active pro-inflammatory cytokine, which is responsible for clinical and laboratory findings in hereditary and acquired auto-inflammatory disorders. Blocking IL-1 activity…
Abstract Number: 1196 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-981, an Anti–Interleukin-1α/β Dual Variable Domain (DVD) Immunoglobulin, in Subjects with Knee Osteoarthritis: Results from the Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Trial
Roy Fleischmann¹, Henning Bliddal², Francisco J Blanco³, Thomas J. Schnitzer⁴, Charles Peterfy⁵, Su Chen⁶, Li Wang⁶, Philip G. Conaghan⁷, Francis Berenbaum⁸, Jean-Pierre Pelletier⁹, Johanne Martel-Pelletier⁹, Ole Vaeterlein¹⁰, Wei Liu⁶, Gwen Levy⁶, Lanju Zhang⁶, Jeroen K. Medema⁶ and Marc C. Levesque⁶, ¹University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, ²Parker Institute, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark, ³INIBIC-Instituto de Investigaciones Biomédicas de A Coruña-Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain, ⁴Northwestern Medicine, Feinberg School of Medicine, Chicago, IL, ⁵Spire Sciences, Inc., Boca Raton, FL, ⁶AbbVie Inc., North Chicago, IL, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁸University Pierre & Marie Curie and Inserm, DHU i2B, APHP, Hospital Saint-Antoine, Paris, France, ⁹Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ¹⁰Bioclinica, Hamburg, Germany
Background/Purpose: Animal studies suggested that inhibiting IL-1α/β with ABT-981 may reduce pain and slow structural progression in OA. This study (NCT02087904; ILLUSTRATE-K) assessed the safety…
Abstract Number: 1211 • 2017 ACR/ARHP Annual Meeting
Biomarkers Predictive of Pain Improvement in Knee Osteoarthritis Subjects Treated with the Anti-IL-1α/β Dual Variable Domain Immunoglobulin ABT-981
Sheng Feng¹, Su Chen¹, Li Wang¹, Charles Peterfy², Virginia B. Kraus³, Rajesh Kamath¹, Lanju Zhang¹, Yanping Luo¹, Lu Cui¹, Jeroen K. Medema¹ and Marc C. Levesque¹, ¹AbbVie Inc., North Chicago, IL, ²Spire Sciences, Inc., Boca Raton, FL, ³Duke University School of Medicine, Durham, NC
Background/Purpose: Development of disease-modifying drugs for OA has been challenging, partly due to lack of predictive biomarkers. Our primary objective was to identify baseline (BL)…
Abstract Number: 2083 • 2017 ACR/ARHP Annual Meeting
The Inflammation Induced By Four Types of Calcium Pyrophosphate Crystals Depends on Their Capacity to Stimulate NF-κb and MAPK Pathways
Félix Renaudin¹, Laure Campillo-Gimenez², Pierre Gras³, Christèle Combes⁴, Martine Cohen-Solal¹, Frederic Liote⁵ and Hang-Korng Ea¹, ¹INSERM UMR1132, Paris Diderot University, Paris, France, ²Inserm UMR1132 Bioscar, Paris, France, ³CIRIMAT, INPT-UPS-CNRS, Toulouse, France, ⁴ENSIACET, CIRIMAT, INPT-UPS-CNRS, Toulouse, France, ⁵University Paris Diderot, Paris, France
Background/Purpose: Calcium pyrophosphate (CPP) crystal-induced inflammation is mainly driven by interleukin (IL)-1β. IL-1β production involves a two-step process including the formation of pro-IL-1β through NF-κB…
Abstract Number: 74 • 2017 Pediatric Rheumatology Symposium
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Esraa M. A. Eloseily^1,2, Peter Weiser¹, Hilary Haines³, Melissa Mannion⁴, Matthew L. Stoll¹, Timothy Beukelman¹, Prescott Atkinson⁵ and Randy Q. Cron¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Assiut University, Assiut, Egypt, ³Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatric Allergy and Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Familial, or primary, hemophagocytic lymphohistiocytosis (pHLH), is a rare but highly fatal condition due to mutations in lymphocyte cytolytic pathway genes. Secondary HLH (sHLH),…
Abstract Number: 3 • 2017 Pediatric Rheumatology Symposium
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva², Rayfel Schneider⁴, Isabelle Koné-Paut⁵, Kenneth N. Schikler⁶, Katherine Marzan⁴, Nico Wulffraat², Shai Padeh⁷, Vyacheslav Chasnyk⁷, Carine Wouters⁷, Jasmin B. Kuemmerle-Deschner⁷, Tilmann Kallinich⁷, Bernard Lauwerys⁸, Elie Haddad⁴, Evgeny L Nasonov⁷, Maria Trachana⁷, Olga Vougiouka⁷, Karolynn Leon⁹, Antonio Speziale¹⁰, Karine Lheritier¹⁰, Eleni Vritzali¹¹, Alberto Martini⁷ and Daniel Lovell⁴, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴PRCSG, Cincinnati, OH, ⁵Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁶PRCSG, Cincinatti, OH, ⁷PRINTO-Istituto Gaslini, Genova, Italy, ⁸Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Canakinumab (CAN), a selective human anti-IL1 β monoclonal antibody, had demonstrated its efficacy and safety in patients (pts) with active systemic juvenile idiopathic arthritis…

1
2
3
…
5
Next Page »